Pelthos Therapeutics Inc. (NYSE: PTHS)

Chromocell Therapeutics Corp, known by its stock symbol CHRO, is a clinical-stage biotech company operating in the pharmaceutical industry. The company is dedicated to developing and commercializing new therapeutics to alleviate pain, with a specific focus on selectively targeting the sodium ion-channel known as NaV1.7.

Chromocell Therapeutics Corp's primary business activities revolve around the development and commercialization of its products, as well as licensing agreements with other companies. The company operates in the biotech industry, with a focus on pain management. They have a global presence, with operations in various countries and regions.

The company generates revenue primarily through the development and commercialization of its products, as well as through licensing agreements with other companies. Their primary products include CC8464 and CT2000, which are being developed to treat neuropathic pain and eye pain, respectively. CC8464 has shown promise in addressing certain types of neuropathic pain, including Erythromelalgia (EM) and idiopathic small fiber neuropathy (iSFN), while CT2000 is being developed to treat both acute and chronic eye pain.

In terms of competition, Chromocell Therapeutics Corp stands out due to its unique approach to pain management. The company's focus on selectively targeting the NaV1.7 channel sets it apart from other companies developing pain medications. Its competitive advantages include its proprietary molecule, CC8464, which has shown selectivity for the NaV1.7 channel, and its expertise in developing topical ophthalmic formulations.

The company's primary customers are pharmaceutical companies and research institutions, although the specific names of these customers have not been disclosed. Chromocell Therapeutics Corp is in discussions with several companies regarding potential collaborations, indicating a strong interest in their products and approach.

The global pain management market was valued at approximately $67 billion in 2021 and is expected to grow to $89 billion by 2027, with a compound annual growth rate of 4.65%. Chromocell Therapeutics Corp believes that its products have the potential to capture a significant share of this market.

The company's pipeline includes CC8464 and CT2000, which are being developed to treat neuropathic pain and eye pain, respectively. Additionally, the company is exploring the development of other compounds that may have potential as pain medications. This diversified pipeline allows for a robust approach to pain management, with a focus on addressing various types of pain.

Chromocell Therapeutics Corp has entered into an exclusive licensing agreement with Benuvia Operations LLC for the development and commercialization of three spray formulations: Diclofenac, Rizatriptan, and Ondansetron. The company is currently conducting clinical trials for these products and expects to bring them to market in the future.